Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Premarket Gainers - Cidara Therapeutics, Inc. (CDTX) is up 91% at $203.18 - Binah Capital Group, Inc. (BCG) is up 45% at $2.07 - Invivyd, Inc. (IVVD) is up 42% at $2.52 - Omeros Corporation (OMER) is up 15% at $7.25 - The Oncology Institute, Inc. (TOI) is up 12% at $3.47 - AlphaVest Acquisition Corp (ATMV) is up 11% at $7.99 - ARB IOT Group Limited (ARBB) is up 7% at $7.31 - Hyperion DeFi, Inc. (HYPD) is up 6% at $5.27 - TruGolf Holdings, Inc. (TRUG) is up 6% at $2.02 - Boqii Holding Limited (BQ) is up 5% at $2.24 [3] Premarket Losers - TSS, Inc. (TSSI) is down 40% at $9.12 - StubHub Holdings, Inc. (STUB) is down 20% at $15.02 - ESS Tech, Inc. (GWH) is down 20% at $3.38 - Red Cat Holdings, Inc. (RCAT) is down 17% at $6.38 - WhiteFiber, Inc. (WYFI) is down 15% at $16.81 - New Era Energy & Digital, Inc. (NUAI) is down 13% at $3.66 - NET Power Inc. (NPWR) is down 11% at $2.62 - Korro Bio, Inc. (KRRO) is down 9% at $5.90 - Anavex Life Sciences Corp. (AVXL) is down 8% at $5.20 - Interactive Strength Inc. (TRNR) is down 5% at $2.47 [4]

Group 1: RLX Technology Inc - RLX Technology Inc reported quarterly earnings of 3 cents per share on sales of $158.600 million [1] - Shares of RLX Technology rose 6% to $2.47 in pre-market trading following the earnings report [1] Group 2: Other Stocks in Pre-Market Trading - Cidara Therapeutics, Inc. surged 92% to $203.50 after a Schedule 13D Amendment revealed beneficial ownership of 3.37 million shares [4] - Binah Capital Group, Inc. gained 52.2% to $2.17 after posting stronger-than-expected third-quarter results [4] - Expion360 Inc. rose 42.4% to $1.81 following its third-quarter results [4] - Aspire Biopharma Holdings, Inc. surged 31.2% to $0.1380 in pre-market trading [4] - Invivyd, Inc. gained 28.8% to $2.28 after reporting better-than-expected third-quarter financial results [4] - Milestone Scientific Inc. surged 26.3% to $0.4801 after reporting better-than-expected third-quarter sales [4] - Lazydays Holdings, Inc. gained 23.3% to $1.85 after a previous surge [4] - Omeros Corp gained 12.5% to $7.08 following a narrower-than-expected quarterly loss [4] - Nouveau Monde Graphite Inc rose 10% to $3.25 after a decline the previous day [4] Group 3: Declining Stocks in Pre-Market Trading - TSS Inc tumbled 40.2% to $9.10 after reporting a year-over-year decrease in third-quarter results [4] - enVVeno Medical Corp declined 35.8% to $0.42 after an unfavorable FDA appeal decision [4] - Nuvve Holding Corp fell 29.3% to $0.34 after announcing third-quarter results [4] - ESS Tech Inc shares dipped 24.2% to $3.22 after reporting weak quarterly sales [4] - Direct Digital Holdings Inc fell 18.8% to $0.23 after a significant gain the previous day [4] - StubHub Holdings Inc fell 18.8% to $15.28 after worse-than-expected third-quarter EPS results [4] - Mangoceuticals Inc dipped 17.7% to $0.98 after a decline the previous day [4] - Red Cat Holdings Inc dipped 15.1% to $6.57 after worse-than-expected financial results and a lowered FY25 sales guidance [4] - WhiteFiber Inc fell 13.4% to $17.21 after reporting worse-than-expected financial results [4] - Sobr Safe Inc fell 12.4% to $2.21 after a decline the previous day [4]

Financial Data and Key Metrics Changes - For Q3 2025, Omeros reported a net loss of $30.9 million, or $0.47 per share, compared to a net loss of $25.4 million, or $0.43 per share in Q2 2025 [4][16] - The adjusted net loss, excluding non-cash charges, was $22.1 million, with an adjusted loss per share of $0.34 [5][16] - Cash burn for the quarter was $22 million, with $36.1 million in cash and investments as of September 30, 2025 [5][17] Business Line Data and Key Metrics Changes - The third-quarter results included $8.8 million in non-cash charges related to embedded derivatives associated with debt [4][16] - Research and development expenses were primarily focused on Zaltenibart and Yartemlya [19] Market Data and Key Metrics Changes - The biologics license application for Yartemlya remains under FDA review, with a PDUFA date of December 26, 2025 [9][10] - The marketing authorization application for Yartemlya in Europe is under review, with an anticipated decision in mid-2026 [10] Company Strategy and Development Direction - Omeros announced a definitive agreement with Novo Nordisk for an asset purchase and license transaction valued at up to $2.1 billion [5][6] - The transaction will provide Omeros with $240 million in upfront cash, which will be used to repay existing debt and fund operations [6][17] - The company is preparing for the commercial launch of Yartemlya, having established a national ICD-10 diagnostic code and an associated CPT procedural code [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the approval decision for Yartemlya and the potential for cash flow positivity in 2027 [26] - Engagement with transplant centers and payers has been positive, driven by the drug's demonstrated benefits [11][12] - The company is focused on advancing its pipeline, including MASP-2 small molecules and oncology programs [41][42] Other Important Information - The company expects overall operating expenses in Q4 2025 to be higher than in Q3, primarily due to increased marketing costs [22] - Income from discontinued operations is expected to be in the $5-$6 million range, excluding non-cash adjustments [24] Q&A Session Summary Question: Post-approval launch timeline for narsoplimab - Management indicated that launch preparations are underway and would move quickly upon approval [25] Question: Details on NTAP for Yartemlya - Management confirmed they expect to receive NTAP, which will help defray costs for hospitals [29][30] Question: Labeling discussions with the FDA - Management stated they do not comment on specific FDA discussions but have provided substantial data for both adult and pediatric patients [31][32] Question: Outlook for operating expenses in 2026 - Management expects expenses to increase, contingent on the closing of the Novo deal and FDA approval [39]

Financial Performance - The net loss for the nine months ended September 30, 2025, was $89,801,000, compared to a net loss of $125,457,000 for the same period in 2024, representing a 28.5% improvement[19] - The company reported a basic net loss per share of $0.47 for the three months ended September 30, 2025, compared to $0.56 for the same period in 2024, reflecting a 16.1% improvement[19] - For the nine months ended September 30, 2025, the net loss was $89.8 million, an improvement from a net loss of $125.5 million in the same period of 2024, representing a 28.5% reduction[24] - The company recorded a net loss from discontinued operations of $9.674 million for the three months ended September 30, 2025[130] Assets and Liabilities - Total current assets decreased from $134,120,000 in December 2024 to $71,805,000 in September 2025, a decline of approximately 46.5%[16] - The total liabilities increased from $277,079,000 in December 2024 to $185,706,000 in September 2025, indicating a reduction in the company's debt obligations[16] - The total shareholders' deficit increased from $182,609,000 in December 2024 to $220,478,000 in September 2025, indicating a worsening financial position[16] - Cash and cash equivalents decreased from $3,400,000 in December 2024 to $2,395,000 in September 2025, a decline of approximately 29.5%[16] - The company had cash, cash equivalents, and short-term investments of $36.1 million as of September 30, 2025[40] Expenses - Research and development expenses for the three months ended September 30, 2025, were $15,995,000, down 33.8% from $24,084,000 in the same period of 2024[19] - Selling, general and administrative expenses for the three months ended September 30, 2025, were $10,397,000, a decrease of 8.2% from $11,323,000 in the same period of 2024[19] - Total stock-based compensation for the nine months ended September 30, 2025, was $6.5 million, down from $8.1 million in the same period of 2024[150] - Selling, general and administrative expenses for the nine months ended September 30, 2025, were $31.865 million, down from $37.395 million in the prior year, primarily due to reduced employee compensation expenses[205] Debt and Financing - The company has an ATM equity offering facility allowing for proceeds of up to $150.0 million, with net proceeds of $9.0 million and $15.3 million received during the three and nine months ended September 30, 2025, respectively[46] - The company reduced the aggregate principal balance of its 2026 Notes from $97.9 million to $17.1 million through a Convertible Note Exchange and an Equitization Transaction[56] - The company has an outstanding Term Loan of $67.1 million, secured by a first-priority security interest in its tangible and intangible property[105] - The anticipated transaction with Novo Nordisk is expected to provide $240.0 million in upfront cash, which will be used to repay the Term Loan[108] - The company recorded a premium of $29.3 million related to the repurchase of 2026 Notes, which is amortized as a reduction of term debt and interest expense[53] Clinical Development and Regulatory - The BLA for narsoplimab in TA-TMA was resubmitted to the FDA in March 2025, with a target action date extended to December 26, 2025[34] - The company has completed two Phase 2 clinical trials for zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and is transitioning ongoing programs to Novo Nordisk[30][31] - The company is developing zaltenibart for PNH and C3G, with two Phase 2 trials substantially completed[164] - The company submitted a Marketing Authorization Application for narsoplimab in the EU, expecting an opinion by mid-2026[159] Cash Flow and Operations - Cash used in operating activities for the nine months ended September 30, 2025, was $76.3 million, down from $119.8 million in the prior year[24] - The company maintained a balance of unrestricted cash above $25.0 million, complying with debt covenants throughout the reporting period[41] - The company is unable to estimate long-term costs for the continued development of product candidates due to the unpredictable nature of clinical development activities[203] Future Expectations - The company expects to repay all outstanding obligations related to the Term Loan upon closure of the transaction with Novo Nordisk, anticipated in Q4 2025[128] - The company anticipates that research and development expenses in the fourth quarter of 2025 will be comparable to those in the third quarter[201] - The company expects selling, general and administrative expenses in the fourth quarter of 2025 to be higher than in the third quarter, mainly due to increased marketing expenses for the anticipated launch of narsoplimab[207] - The company expects interest expense for the fourth quarter of 2025 to be higher compared to the third quarter, assuming no remeasurement adjustment to the OMIDRIA contract royalty obligation[213]

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 13, 2025 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: The upfront cash of $240.0 million payable at closing, together with cash on hand, is expected to provide sufficient capital to (i) fund the repayment at the closing of all outstanding ...

Core Points - Omeros Corporation will announce its financial results for Q3 2025 on November 13, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments [1] Company Overview - Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for complement-mediated diseases, cancers, and addictive disorders [5] - The lead product, narsoplimab, is under regulatory review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [5] - OMS1029, a long-acting MASP-2 inhibitor, has completed Phase 1 clinical trials, while zaltenibart (OMS906) is in development for PNH and C3 glomerulopathy [5] - Novo Nordisk has acquired global rights to zaltenibart, including associated intellectual property [5] - Omeros' pipeline includes OMS527, a phosphodiesterase 7 inhibitor for cocaine use disorder, funded by the National Institute on Drug Abuse [5]

Group 1 - Omeros Corporation is identified as a hot stock with significant upside potential, with H.C. Wainwright raising its price target from $9 to $20 while maintaining a Buy rating [1][2] - The company has entered into an asset purchase and license agreement with Novo Nordisk for zaltenibart, which is expected to enhance its market position [1][3] - Omeros will receive an upfront cash payment of $240 million, with additional potential payments of $510 million tied to development and approval milestones, and up to $1.3 billion in sales-based milestone payments [2] Group 2 - Omeros is a clinical-stage biopharmaceutical company focused on developing small-molecule and protein therapeutics for immunologic diseases [4] - Novo Nordisk operates in the pharmaceutical sector, specializing in diabetes, obesity care, and rare diseases, indicating a strong partnership potential for Omeros [3]

Core Insights - Momentum investors are attracted to fast-growing stocks, particularly in the biopharmaceuticals industry, which presents significant growth potential [2][3] Group 1: uniQure N.V. (NASDAQ: QURE) - uniQure has seen a significant share price increase, with a current price of $59.91 and a 12-month price forecast of $71.75, indicating a 19.76% upside potential [3][5] - The company is known for its adeno-associated viral (AAV) vector platform and has promising drug candidates, including AMT-130 for Huntington's disease and AMT-260 for epilepsy [3][4] - As of Q2, uniQure had $377 million in cash, providing operational runway into 2027 [4] Group 2: Omeros Corp. (NASDAQ: OMER) - Omeros experienced a price spike in mid-October after Novo Nordisk acquired licensing rights to its drug Zaltenibart for $240 million, with a 12-month price forecast of $27.50, representing a 255.30% upside [6][8] - The current price is $7.74, with analysts rating it a Moderate Buy based on 8 ratings [7][9] - Despite a recent price drop, analysts remain optimistic, projecting a potential upside of nearly 244% [9] Group 3: Stardust Power Inc. (NASDAQ: SDST) - Stardust Power, a micro-cap battery tech firm, has a current price of $4.52 and a 12-month price forecast of $51.13, indicating a potential upside of 1,031.08% [10][12] - The company has secured agreements to develop an electric substation and to secure lithium carbonate, which positions it for growth amid rising domestic demand [10][11] - Analysts are bullish, with four out of six rating it a Buy, reflecting confidence in its future prospects [12]

Core Insights - Omeros Corporation has entered into a definitive asset purchase and license agreement with Novo Nordisk for the clinical-stage drug zaltenibart, which targets rare blood and kidney disorders [1][3] - The transaction is expected to close in Q4 2025, granting Novo Nordisk exclusive global rights to develop and commercialize zaltenibart [2][3] - Zaltenibart is a humanized monoclonal antibody designed to inhibit MASP-3, a key activator in the complement system, which is implicated in various rare diseases [2][3] Company Overview - Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for immunologic diseases [4] - Novo Nordisk is a global pharmaceutical company that operates in two segments: Diabetes and Obesity Care, and Rare Disease, and is involved in research, development, manufacturing, and distribution of pharmaceutical products [4] Clinical Data - Omeros has reported positive Phase 2 clinical trial data for zaltenibart in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, indicating the compound's good tolerance in trials [3] - Novo Nordisk views zaltenibart as having a novel mode of action that could lead to a best-in-class treatment for complement-mediated diseases, including PNH and various renal diseases [3]